Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunotherapy of cancer in the era of checkpoint inhibitor.

Literature DB >> 34878618

Immunotherapy of cancer in the era of checkpoint inhibitor.

Abstract

Application of immunotherapy has revolutionized treatment of number of malignancies. We present a review of immunotherapy approaches, early-phase data of number of new immunotherapeutic targets in melanoma, cutaneous squamous cell carcinoma, Merkel cell cancer, and non-small cell lung cancer.

Entities: Chemical

Keywords: Checkpoint inhibitors; Cytokines; Immunotherapy; LAG-3; MCC; Melanoma; NSCLC; TIM-3; cSCC

Mesh：

Year: 2021 PMID： 34878618 DOI： 10.1007/s10585-021-10132-9

Source DB: PubMed Journal: Clin Exp Metastasis ISSN： 0262-0898 Impact factor: 5.150

24 in total

1. Growth and development of the bovine as related to certain endocrine factors.

Authors: S E Curl; M A Fennell; D W Zinn; R C Albin
Journal: J Anim Sci Date: 1968-07 Impact factor: 3.159

2. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.

Authors: Seng-Ryong Woo; Meghan E Turnis; Monica V Goldberg; Jaishree Bankoti; Mark Selby; Christopher J Nirschl; Matthew L Bettini; David M Gravano; Peter Vogel; Chih Long Liu; Stephanie Tangsombatvisit; Joseph F Grosso; George Netto; Matthew P Smeltzer; Alcides Chaux; Paul J Utz; Creg J Workman; Drew M Pardoll; Alan J Korman; Charles G Drake; Dario A A Vignali
Journal: Cancer Res Date: 2011-12-20 Impact factor: 12.701

3. Interactions of C12 surfactants with the skin: studies on enzyme release and percutaneous absorption in vitro.

Authors: W T Gibson; M R Teall
Journal: Food Chem Toxicol Date: 1983-10 Impact factor: 6.023

4. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors: James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal: N Engl J Med Date: 2015-05-31 Impact factor: 91.245

5. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

Authors: Fumiya Hirano; Katsumi Kaneko; Hideto Tamura; Haidong Dong; Shengdian Wang; Masao Ichikawa; Cecilia Rietz; Dallas B Flies; Julie S Lau; Gefeng Zhu; Koji Tamada; Lieping Chen
Journal: Cancer Res Date: 2005-02-01 Impact factor: 12.701

6. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors: Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal: Proc Natl Acad Sci U S A Date: 2010-02-16 Impact factor: 11.205

7. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.

Authors: Neil H Segal; Theodore F Logan; F Stephen Hodi; David McDermott; Ignacio Melero; Omid Hamid; Henrik Schmidt; Caroline Robert; Vanna Chiarion-Sileni; Paolo A Ascierto; Michele Maio; Walter J Urba; Tara C Gangadhar; Satyendra Suryawanshi; Jaclyn Neely; Maria Jure-Kunkel; Suba Krishnan; Holbrook Kohrt; Mario Sznol; Ronald Levy
Journal: Clin Cancer Res Date: 2016-10-18 Impact factor: 12.531

8. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.

Authors: Neil H Segal; Aiwu R He; Toshihiko Doi; Ronald Levy; Shailender Bhatia; Michael J Pishvaian; Rossano Cesari; Ying Chen; Craig B Davis; Bo Huang; Aron D Thall; Ajay K Gopal
Journal: Clin Cancer Res Date: 2018-03-16 Impact factor: 12.531

Review 9. Neoantigens in cancer immunotherapy.

Authors: Ton N Schumacher; Robert D Schreiber
Journal: Science Date: 2015-04-03 Impact factor: 47.728

10. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.

Authors: Ben Tran; Richard D Carvajal; Aurelien Marabelle; Sandip Pravin Patel; Patricia M LoRusso; Erik Rasmussen; Gloria Juan; Vijay V Upreti; Courtney Beers; Gataree Ngarmchamnanrith; Patrick Schöffski
Journal: J Immunother Cancer Date: 2018-09-25 Impact factor: 13.751

1 in total

1. Introduction: Novel Frontiers in Cancer Metastasis.

Authors: Stanley P Leong; Jonathan S Zager
Journal: Clin Exp Metastasis Date: 2022-02-22 Impact factor: 5.150

1 in total